CA2792413C - Composition for the anti-cancer metastasis containing dlk1-fc fusion protein as an effective ingredient - Google Patents

Composition for the anti-cancer metastasis containing dlk1-fc fusion protein as an effective ingredient Download PDF

Info

Publication number
CA2792413C
CA2792413C CA2792413A CA2792413A CA2792413C CA 2792413 C CA2792413 C CA 2792413C CA 2792413 A CA2792413 A CA 2792413A CA 2792413 A CA2792413 A CA 2792413A CA 2792413 C CA2792413 C CA 2792413C
Authority
CA
Canada
Prior art keywords
dlk1
cancer
fusion protein
cell
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2792413A
Other languages
English (en)
French (fr)
Other versions
CA2792413A1 (en
Inventor
Young Woo Park
Kiwon Jo
Donghee Lee
Jung Yu
Ji Hyun Park
Chan-Woong Park
Eun Jin Kim
Yun Jung Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Publication of CA2792413A1 publication Critical patent/CA2792413A1/en
Application granted granted Critical
Publication of CA2792413C publication Critical patent/CA2792413C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2792413A 2010-03-16 2010-04-13 Composition for the anti-cancer metastasis containing dlk1-fc fusion protein as an effective ingredient Expired - Fee Related CA2792413C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2010-0023180 2010-03-16
KR1020100023180A KR100982170B1 (ko) 2010-03-16 2010-03-16 ＤＬＫ１―Ｆｃ 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물
PCT/KR2010/002277 WO2011115323A1 (ko) 2010-03-16 2010-04-13 디엘케이원-에프씨 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물

Publications (2)

Publication Number Publication Date
CA2792413A1 CA2792413A1 (en) 2011-09-22
CA2792413C true CA2792413C (en) 2015-12-01

Family

ID=43010111

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2792413A Expired - Fee Related CA2792413C (en) 2010-03-16 2010-04-13 Composition for the anti-cancer metastasis containing dlk1-fc fusion protein as an effective ingredient

Country Status (11)

Country Link
US (1) US8785392B2 (ko)
EP (1) EP2548887B1 (ko)
JP (1) JP5367905B2 (ko)
KR (1) KR100982170B1 (ko)
CN (1) CN102341408B (ko)
AU (1) AU2010348423B2 (ko)
BR (1) BR112012023416A2 (ko)
CA (1) CA2792413C (ko)
MX (1) MX342222B (ko)
RU (1) RU2531756C2 (ko)
WO (1) WO2011115323A1 (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100982170B1 (ko) 2010-03-16 2010-09-15 한국생명공학연구원 ＤＬＫ１―Ｆｃ 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물
WO2012138102A2 (ko) * 2011-04-04 2012-10-11 한국생명공학연구원 Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물
WO2012138100A2 (ko) * 2011-04-04 2012-10-11 한국생명공학연구원 Ｄｌｋ１ 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2ｂ 억제제
KR101461706B1 (ko) 2011-04-04 2014-11-18 한국생명공학연구원 Ｄｌｋ１ 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2ｂ 억제제
CN102778566B (zh) * 2011-05-07 2016-01-13 上海市肿瘤研究所 Dlk1在肝癌诊断及预后判断中的应用
KR101995751B1 (ko) * 2012-01-05 2019-07-03 주식회사 와이바이오로직스 Ｄｌｋ１ 세포 외 수용성 도메인을 유효성분으로 포함하는 미오스타틴 저해제
WO2014129590A1 (ja) * 2013-02-21 2014-08-28 国立大学法人九州大学 Ｃｙｃｌｉｎ Ｄ１遺伝子発現抑制剤および抗腫瘍剤
CN105765063B (zh) 2013-09-30 2021-05-07 中外制药株式会社 应用改变的辅助噬菌体制备抗原结合分子的方法
CN104711341B (zh) * 2013-12-17 2019-10-22 上海市肿瘤研究所 Dlk1基因在制备胃肠道间质瘤诊断试剂中的应用
WO2019050362A2 (ko) * 2017-09-08 2019-03-14 주식회사 와이바이오로직스 인간 dlk1에 대한 항체 및 이의 용도
CN108130311B (zh) * 2017-12-19 2020-12-08 柴怡 一种人原代结肠癌肝转移细胞株hcs1220

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
ES2151542T3 (es) * 1992-12-11 2001-01-01 Us Health Gen del tipo delta expresado en tumores neuroendocrinos.
EP0938332A4 (en) * 1996-03-01 2003-05-28 Imclone Systems Inc USE OF DELTA-LIKE PROTEINS TO INHIBIT THE DIFFERENTIATION OF STEM CELLS
US20020064855A1 (en) * 1999-08-20 2002-05-30 Ihor Lemischka Genes that regulate hematopoietic blood forming stem cells and uses thereof
JP2007531707A (ja) * 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
US8227578B2 (en) 2006-11-10 2012-07-24 Abe, Ikubo & Katayama Anti-human dlk-1 antibody showing anti-tumor activity in vivo
ES2527521T3 (es) * 2008-03-17 2015-01-26 Livtech Inc. Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral
KR100982170B1 (ko) 2010-03-16 2010-09-15 한국생명공학연구원 ＤＬＫ１―Ｆｃ 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물

Also Published As

Publication number Publication date
EP2548887B1 (en) 2015-05-27
US8785392B2 (en) 2014-07-22
WO2011115323A1 (ko) 2011-09-22
MX2012010560A (es) 2012-12-10
CN102341408B (zh) 2014-09-10
JP5367905B2 (ja) 2013-12-11
EP2548887A1 (en) 2013-01-23
US20130202592A1 (en) 2013-08-08
BR112012023416A2 (pt) 2017-03-21
CA2792413A1 (en) 2011-09-22
CN102341408A (zh) 2012-02-01
KR100982170B1 (ko) 2010-09-15
AU2010348423A1 (en) 2012-10-25
RU2531756C2 (ru) 2014-10-27
AU2010348423B2 (en) 2014-04-10
JP2012513775A (ja) 2012-06-21
MX342222B (es) 2016-09-21
EP2548887A4 (en) 2013-12-04
RU2012143943A (ru) 2014-04-27

Similar Documents

Publication Publication Date Title
CA2792413C (en) Composition for the anti-cancer metastasis containing dlk1-fc fusion protein as an effective ingredient
Hand et al. Expression of laminin receptor in normal and carcinomatous human tissues as defined by a monoclonal antibody
TW393489B (en) Recombinant antibodies for human therapy
US7070959B1 (en) Modified chimeric polypeptides with improved pharmacokinetic properties
JPH01502669A (ja) 精製された血小板由来の成長因子及びその精製方法
Evans et al. Rapid expression of an anti-human C5 chimeric Fab utilizing a vector that replicates in COS and 293 cells
CN108135968A (zh) 嵌合多肽组装体及其制备和使用方法
CN101802002A (zh) 结合人蛋白酪氨酸磷酸酶β（HPTPβ）的抗体及其用途
CN110090295B (zh) Ephrin-B1在制备治疗炎症性肠病的药物中的用途
EA011859B1 (ru) Соединения для адресной доставки препарата к ткани или органу-мишени
CN106188282B (zh) 抗诺如病毒gi.1型鼠源单克隆抗体的制备和应用
JPH07504802A (ja) 遺伝子操作抗体
MARESH et al. Cloning and expression of the gene for the melanoma-associated ME20 antigen
CN102936283A (zh) 抗人cd146的单克隆抗体，包含其的组合物，检测可溶性cd146的方法
US7074411B1 (en) α-β C4BP-type recombinant heteromultimeric proteins
CN102850456A (zh) 一种血管内皮生长因子人源化单克隆抗体及其制备方法和用途
CN101896502A (zh) 抗人TNFα单抗、分子进化及其应用
EP0269677A1 (en) ASSAYS AND ANTIBODIES FOR N-$i(myc) PROTEINS
CN100398155C (zh) 用于预防反刍动物捻转血矛线虫病的dna疫苗
CN105461807B (zh) 肿瘤相关基因tp53表位多肽单克隆抗体及其应用
JP3385408B2 (ja) 新規蛋白質とその抗体、並びにその新規蛋白質の製造方法
CN106995801A (zh) 抗树鼩cd4分子单克隆抗体及分泌该抗体的杂交瘤细胞株与应用
CN102336834B (zh) 全人TNFα-Fab抗体及其PEG化抗体
CN103275212B (zh) 抗人cd146的单克隆抗体，包含其的组合物，检测可溶性cd146的方法
FI106129B (fi) Menetelmät valmistaa muuntuneita CD44-pintaproteiineja ja näitä proteiineja vastaan vaikuttavia vasta-aineita

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190415